Pharmacy Scholarship: Zac Cox

Cox ZL, Lai P, Lewis CM, Lindenfeld J. Body mass index and all-cause readmissions following acute heart failure hospitalization. Int J Obes (Lond). 2020;44(6):1227-1235. doi:10.1038/s41366-019-0518-6

Cox ZL, Lai P, Lewis CM, Lindenfeld J. Change in admission blood glucose from chronic glycemic status in acute heart failure hospitalization and 30-day outcomes: A retrospective analysis. Int J Cardiol. 2020;299:180-185. doi:10.1016/j.ijcard.2019.07.069

Cox ZL, Lai P, Lindenfeld J. Decreases in acute heart failure hospitalizations during COVID-19. Eur J Heart Fail. 2020;22(6):1045-1046. doi:10.1002/ejhf.1921

Cox ZL, Hung R, Lenihan DJ, Testani JM. Diuretic strategies for loop diuretic resistance in acute heart failure: the 3T trial. JACC Heart Fail. 2020;8(3):157-168. doi:10.1016/j.jchf.2019.09.012

Felker GM, Ellison DH, Mullens W, Cox ZL, Testani JM. Diuretic therapy for patients with heart failure: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020;75(10):1178-1195. doi:10.1016/j.jacc.2019.12.059

Cox ZL, Sury K, Rao VS, Ivey-Miranda JB, Griffin M, Mahoney D, Gomez N, Fleming JH, Inker LA, Coca SG, Turner J, Wilson FP, Testani JM. Effect of loop diuretics on the fractional excretion of urea in decompensated heart failure. J Card Fail. 2020;doi:10.1016/j.cardfail.2020.01.019

Griffin M, Rao VS, Ivey-Miranda J, Fleming, J, Mahoney D, Maulion C, Suda N, Siwakoti K, Ahmad T, Jacoby D, Riello R, Bellumkonda L, Cox Z, Collins S, Jeon S, Turner JM, Wilson FP, Butler J, Inzucchi SE, Testani JM. Empagliflozin in heart failure: diuretic and cardiorenal effects. Circulation. 2020;142(11):1028-1039. doi:10.1161/circulationaha.120.045691

Cox ZL, Testani JM. Loop diuretic resistance complicating acute heart failure. Heart Fail Rev. 2020;25(1):133-145. doi:10.1007/s10741-019-09851-9

Cox ZL, Fleming J, Ivey-Miranda J, Griffin M, Mahoney D, Jackson K, Hodson DZ, Thomas D Jr, Gomez N, Rao VS, Testani JM. Mechanisms of Diuretic Resistance Study: design and rationale. ESC Heart Fail. 2020;doi:10.1002/ehf2.12949

Gorodeski EZ, Goyal P, Cox ZL, Thibodeau JT, Reay RE, Rasmusson K, Rogers JG, Starling RC. Virtual visits for care of patients with heart failure in the era of COVID-19: a statement from the Heart Failure Society of America. J Card Fail. 2020;26(6):448-456. doi:10.1016/j.cardfail.2020.04.008

Cox ZL, Stevenson LW. The weight of evidence for diuretics and parachutes. J Am Coll Cardiol. 2020;76(6):680-683. doi:10.1016/j.jacc.2020.06.044

Xiong L, Chinaeke EE, Lu K, Lenihan DJ, Merritt TE, Cox ZL. Evaluation of severe myalgia induced by continuous-infusion bumetanide in patients with acute heart failure. Pharmacotherapy. 2019.

Sabato LA, Johnson DC, Haglund N, Keebler M, Cox ZL. Pharmacokinetics of sildenafil in patients with a left ventricular assist device: A word of caution. ASAIO J. 2019;65(5):530-532. doi:10.1097/mat.0000000000000886

Charokopos A, Griffin M, Rao VS, Inker, L, Sury K, Asher J, Turner J, Mahoney D, Cox ZL, Wilson FP, Testani J. M. Serum and urine albumin and response to loop diuretics in heart failure. Clin J Am Soc Nephrol. 2019;14(5):712-718.

Cox ZL, Lai P, Lewis CM, Lindenfeld J, Collins SP, Lenihan DJ. Customizing national models for a medical center's population to rapidly identify patients at high risk of 30-day all-cause hospital readmission following a heart failure hospitalization. Heart Lung. 2018;47(4):290-296.

Cox ZL, Lai P, Lewis CM, Lenihan DJ. Centers for Medicare and Medicaid services' readmission reports inaccurately describe an institution's decompensated heart failure admissions. Clin Cardiol. 2017;40(9):620-625.

Tunney RK, Jr., Johnson DC, Wang L, Cox ZL. Impact of pharmacist intervention to increase compliance with guideline-directed statin therapy during an acute coronary syndrome hospitalization. Ann Pharmacother. 2017;51(5):394-400.

Sabato LA, Mendes LA, Cox ZL. Restrictive cardiomyopathy associated with long-term use of hydroxychloroquine for systemic lupus erythematosus. J Pharm Pract. 2017;30(5):571-575.

Cox ZL, Lewis CM, Lai P, Lenihan DJ. Validation of an automated electronic algorithm and "dashboard" to identify and characterize decompensated heart failure admissions across a medical center. Am Heart J. 2017;183:40-48.

Haglund NA, Burdorf A, Jones T, Shostrom V, Um J, Ryan T, Shillcutt S, Fischer P, Cox ZL, Raichlin E, Anderson DR, Lowes BD, Dumitru I. Inhaled milrinone after left ventricular assist device implantation. J Card Fail. 2015;21(10):792-797.

Haglund NA, Cox ZL, Lee JT, Song Y, Keebler ME, DiSalvo TG, Maltais S, Lenihan DJ, Wigger MA. Are peripherally inserted central catheters associated with increased risk of adverse events in status 1B patients awaiting transplantation on continuous intravenous milrinone? J Card Fail. 2014;20(9):630-637. doi: 10.1016/j.cardfail.2014.06.004

Powers JS, Cox ZL, Young J, Howell M, DiSalvo T. Critical pathways: Implementation of the Coleman Care Transitions Program in individuals hospitalized with congestive heart failure. J Am Geriatr Soc. 2014;62(12):2442-2444. 10.1111/jgs.13174

Cox ZL, Lenihan DJ. Loop diuretic resistance in heart failure: Resistance etiology-based strategies to restoring diuretic efficacy. J Card Fail. 2014;20(8):611-622.

Cox ZL, McCoy AB, Matheny ME, Bhave G, Peterson NB, Siew ED, Lewis J, Danciu I, Bian A, Shintani A, Ikizler TA, Neal EB, Peterson JF. Adverse drug events during AKI and its recovery. Clin J Am Soc Nephrol. 2013;8(7):1070-1078.

Cox ZL, Calcutt MW, Morrison TB, Akers WS, Davis MB, Lenihan DJ. Elevation of plasma milrinone concentrations in stage D heart failure associated with renal dysfunction. J Cardiovasc Pharmacol Ther. 2013;18(5):433-438. doi: 10.1177/1074248413489773

McCoy AB, Cox ZL, Neal EB, Waitman LR, Peterson NB, Bhave G, Siew ED, Danciu I, Lewis JB, Peterson JF. Real-time pharmacy surveillance and clinical decision support to reduce adverse drug events in acute kidney injury: A randomized, controlled trial. Appl Clin Inform. 2012;3(2):221-238.

Cox ZL, Nelsen CL, Waitman LR, McCoy JA, Peterson JF. Effects of clinical decision support on initial dosing and monitoring of tobramycin and amikacin. Am J Health Syst Pharm. 2011;68(7):624-632.

Wilson NS, Hudson JQ, Cox ZL, King T, Finch CK. Hyperkalemia-induced paralysis. Pharmacotherapy. 2009;29(10):1270-1272. 10.1592/phco.29.10.1270